APH vs PRLD · P/E 40, rev $23.09B vs rev $6.5M
Amphenol Corporation (APH) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
APH currently screens at market cap $170.77B and trailing P/E 39.9. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the APH and PRLD stock pages for the full models.
Not investment advice.